Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com
Quote | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Last: | $3.0388 |
---|---|
Change Percent: | -0.69% |
Open: | $3.07 |
Close: | $3.06 |
High: | $3.1 |
Low: | $2.942 |
Volume: | 594,585 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Cellectar Biosciences Inc. (NASDAQ:CLRB)
2024-03-28 09:15:05 ET Oppenheimer analyst issues OUTPERFORM recommendation for CLRB on March 28, 2024 07:33AM ET. The previous analyst recommendation was Outperform. CLRB was trading at $3.635 at issue of the analyst recommendation. Historical Analyst Recommendations ...
2024-03-27 12:27:02 ET Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Conference Call March 27, 2024, 08:30 AM ET Company Participants Jim Caruso - President and CEO Andrei Shustov - SVP, Medical Jarrod Longcor - COO Shane Lea - Chief Commercial Officer ...
Message Board Posts | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for First Quarter 2023 and Pro | whytestocks | investorshangout | 05/04/2023 12:55:45 PM |
whytestocks: $CLRB News Article - Cellectar Biosciences Reports Complete Response in a Relapsed/Refr | whytestocks | investorshangout | 02/28/2023 4:40:48 PM |
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Source:Edgar (US | abracky | investorshub | 12/12/2022 5:44:16 AM |
Look at $PSTV - All the due diligence | The Ultimate Choice | investorshub | 09/06/2022 1:47:38 PM |
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for Second Quarter 2022 | whytestocks | investorshangout | 08/05/2022 5:01:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
2024-03-28 09:15:05 ET Oppenheimer analyst issues OUTPERFORM recommendation for CLRB on March 28, 2024 07:33AM ET. The previous analyst recommendation was Outperform. CLRB was trading at $3.635 at issue of the analyst recommendation. Historical Analyst Recommendations ...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ende...